Compare FOUR & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FOUR | BEAM |
|---|---|---|
| Founded | 1999 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 2.6B |
| IPO Year | 2020 | 2019 |
| Metric | FOUR | BEAM |
|---|---|---|
| Price | $39.16 | $23.29 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 25 | 15 |
| Target Price | ★ $52.86 | $52.15 |
| AVG Volume (30 Days) | 1.7M | ★ 1.7M |
| Earning Date | 11-05-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 82.31 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $4,180,000,000.00 | $24,000.00 |
| Revenue This Year | $22.40 | N/A |
| Revenue Next Year | $13.37 | $29.19 |
| P/E Ratio | $27.53 | ★ N/A |
| Revenue Growth | 25.50 | ★ 33.33 |
| 52 Week Low | $34.56 | $20.23 |
| 52 Week High | $77.50 | $38.26 |
| Indicator | FOUR | BEAM |
|---|---|---|
| Relative Strength Index (RSI) | 45.88 | 40.52 |
| Support Level | $34.92 | $22.49 |
| Resistance Level | $51.46 | $26.72 |
| Average True Range (ATR) | 1.63 | 1.17 |
| MACD | 0.40 | 0.01 |
| Stochastic Oscillator | 65.23 | 4.89 |
Shift4 Payments Inc is an independent provider of software and payment processing solutions in the U.S., expanding internationally. Its payments platform offers integrated products and services across in-store, online, mobile and tablet-based channels, including end-to-end payment processing, merchant acquiring services, a proprietary omni-channel gateway, eCommerce capabilities, and reporting tools. The company distributes its services through internal sales teams and partners, including independent software vendors (ISVs) and value-added resellers (VARs). Revenue is predominantly recurring, derived mainly from processing fees and subscription revenue from POS software, business intelligence tools and other technology solutions. The company derives maximum revenue from the United States.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.